Peptide record

TPDB64375

RALA peptide Cell-penetrating Peptides standard
24 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB64375
RALA peptide
Cell-penetrating Peptides
Delivery and barrier-penetrating peptides
CPPsite3.0 Peptipedia PerseuCPP
standard
No
A 24-aa standard natural cell-penetrating peptides peptide sequence curated from CPPsite3.0, Peptipedia, and PerseuCPP, with an available 3D structural model.
Sequence
WEARLARALARALARHLARALARA
Physicochemical Analysis
C118H203N45O27
NDCQGIKMFPSTYV
A
2684.20
12.70
7
1
16
+5
1.49
0.100
122.92
Mammalian: 2.8 hour Yeast: 3 min E.coli: 2 min
5500
204.90
0
Residue Composition
number
10
A
6
R
0
N
0
D
0
C
1
E
0
Q
0
G
1
H
0
I
5
L
0
K
0
M
0
F
0
P
0
S
0
T
1
W
0
Y
0
V
Amino Acid Distribution
A: 10 R: 6 N: 0 D: 0 C: 0 E: 1 Q: 0 G: 0 H: 1 I: 0 L: 5 K: 0 M: 0 F: 0 P: 0 S: 0 T: 0 W: 1 Y: 0 V: 0
Chemical Descriptors
24
C118H203N45O27
2684.20
12.70
+5
1.49
0.100
Free
L
Amphipathic
Linear
Free
N[C@@H](CC1=C(C(=NC1)C)CC)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](Cc1[nH]cnc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](C)C(=O)O
Evidence Records 1 records
Evidence 1 Activity

Activity

Cell-penetrating Peptides

Target

ZR-75-1 human breast cancer, PC-3 human prostate cancerand NCTC-929 murine fibroblast cell lines

Source & Reference

CPPsite3.0
CPPsite3

Other

Source Activity Label Source Definition
Cell-penetrating Peptides
CPPsite3.0 experimentally validated cell-penetrating peptide annotation.
Natural residues Linear L Amphipathic
Synthetic
Nucleic acid (pDNA)
Readily traversed the plasma membrane of both cancer and fibroblast cell lines and elicited reporter-gene expression following intravenous delivery in vivo
Endocytosis
In vitro and in vivo
CCCSSHHHHHHHHHCCHHHHTTC
Additional Detail Fields 1 fields
CCCSSHHHHHHHHHCCHHHHTTC